We are only 4 years behind overall schedule and behind the recent accelerated schedule. IMHO market is now given nil credence to previous guidance and forecast of accelerated policy. Market advised OCT23 that policy momentum would not be achieved and was revised lower and take longer. The original 95% or revised 85% by June24 was never on the table like we were led to believe. The policy work was not done. Refer the response to Shane Storey question during 24Q4 call. "So, it's kind of hard to give a sense of the timing, but we are working with -- [ Chelsea ] and the reimbursement team is working with both a couple of additional national payers, but also some of the local payers that still need additional kind of data."
So here we are, some policy change and no follow through from the 23Q4 sales print and back at the starting post of $0.059. existing contracts locked into lower pricing regime from lack of follow through with policy change.
My Summary, Market had lost confidence in previously Dream Team; their narrative has not held up to expectations and most owners are in drawdown through that poor performance and lack of execution follow through. The new Dream Team needs to rebuild the lost confidence (including prove their execution skills in this business) by increasing sales using their targeted approach to get the best pricing. Second best USA print in 3 years was Q424 and increased average pricing from 24HY $1200 to 24Q4 $1400 is a start. Still working through the 24Q4 data. There is a better way. Acclivity
IPD Price at posting:
5.9¢ Sentiment: Buy Disclosure: Held
